MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.35 3.05

Buy Sell

Overview

Share price change

24h

Current

Min

1.27

Max

1.37

Key metrics
By Trading Economics
Income	2.7M -24M
EPS	-0.354
Employees	49
EBITDA	-5.3M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+111.9% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-8.4M 73M
Previous open	-1.7
Previous close	1.35

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 kwi 2026, 22:56 UTC

Major News Events

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 kwi 2026, 20:50 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 kwi 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 kwi 2026, 23:23 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 kwi 2026, 23:07 UTC

Earnings

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 kwi 2026, 23:02 UTC

Major News Events

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 kwi 2026, 23:00 UTC

Major News Events

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 kwi 2026, 22:39 UTC

Earnings

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 kwi 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 kwi 2026, 22:00 UTC

Major News Events

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 kwi 2026, 22:00 UTC

Major News Events

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 kwi 2026, 22:00 UTC

Major News Events

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 kwi 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 kwi 2026, 21:31 UTC

Major News Events

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 kwi 2026, 20:38 UTC

Earnings

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 kwi 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 kwi 2026, 20:16 UTC

Acquisitions, Mergers, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 kwi 2026, 20:13 UTC

Acquisitions, Mergers, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 kwi 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 kwi 2026, 20:07 UTC

Acquisitions, Mergers, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

111.9% upside

12 Months Forecast

Average 2.67 USD 111.9%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.